wAIHA
FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia
Johnson & Johnson (NYSE: JNJ) announced on August 24 that the FDA has approved IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA) in adults and adolescents 12 and older who are currently or previously treated with corticosteroids, making it the first FDA-approved therapy specifically for the disease. The approval followed FDA Priority Review and is…
